Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Polarean Imaging ( (GB:POLX) ) has provided an announcement.
Polarean Imaging PLC announced that all resolutions were passed at their recent General Meeting, leading to the cancellation of their shares from trading on AIM, effective December 23, 2025. The company will re-register as a private limited company and has arranged a Matched Bargain Facility to assist shareholders in trading shares post-cancellation. This facility, provided by J P Jenkins, will enable shareholders to buy or sell shares through matched orders, although liquidity is not guaranteed. The move reflects a strategic shift in Polarean’s operations and may impact shareholder trading flexibility.
The most recent analyst rating on (GB:POLX) stock is a Hold with a £0.17 price target. To see the full list of analyst forecasts on Polarean Imaging stock, see the GB:POLX Stock Forecast page.
Spark’s Take on GB:POLX Stock
According to Spark, TipRanks’ AI Analyst, GB:POLX is a Neutral.
Polarean Imaging’s overall stock score reflects significant financial challenges, including persistent losses and negative cash flow, which weigh heavily on the score. While technical indicators and valuation present additional concerns, recent corporate events and strategic expansions offer some optimism for future growth. The earnings call provides a cautiously optimistic outlook, but immediate financial health remains a critical concern.
To see Spark’s full report on GB:POLX stock, click here.
More about Polarean Imaging
Polarean Imaging PLC is a medical imaging technology company focused on revolutionizing pulmonary medicine by providing direct visualization of lung function through MRI. The company has developed XENOVIEW®, the first and only FDA-approved hyperpolarized Xenon MRI inhaled contrast agent, aimed at addressing the needs of over 500 million patients worldwide suffering from chronic respiratory diseases. Polarean is committed to optimizing lung health with its non-invasive, radiation-free pulmonary functional MRI platform, which includes a proprietary Xenon gas blend, a gas hyperpolarization system, software, and accessories.
YTD Price Performance: -88.30%
Average Trading Volume: 16,886,235
Technical Sentiment Signal: Sell
Current Market Cap: £1.87M
For a thorough assessment of POLX stock, go to TipRanks’ Stock Analysis page.